A Phase 1, Randomized, Double-blind, Placebo-controlled Study To Assess Safety, Tolerability, And Pharmacokinetics Of Single Escalating Oral Doses Of Pf-06815345, As Well As Characterize The Pharmacokinetics Of Two Formulations And Effect Of Food On Pharmacokinetics Of One Formulation Of Pf-06815345 Administered To Healthy Adult Subjects
Latest Information Update: 24 Aug 2020
At a glance
- Drugs PF 6815345 (Primary)
- Indications Hypercholesterolaemia
- Focus Adverse reactions
- Sponsors Pfizer
- 02 Apr 2016 Planned End Date changed from 1 Mar 2016 to 1 Jul 2016 as reported by ClinicalTrials.gov record.
- 02 Apr 2016 Planned primary completion date changed from 1 Mar 2016 to 1 May 2016 as reported by ClinicalTrials.gov record.
- 02 Apr 2016 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.